Despite growing evidence for the efficacy of anti-angiogenic therapy in non-oncogene driven NSCLC and EGFR mutated NSCLC, there remain limited data on the efficacy of anti-angiogenic therapy in ALK rearranged patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.